Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

UNBELIEVABLE: Bridgebio pharma posts promising data from gene therapy trial in ultra rare disease - The Untold Story

  • BridgeBio Pharma Inc (NASDAQ:BBIO) announced promising pharmacodynamic data from the first two participants dosed in CANaspire Phase 1/2 trial of BBP-812, gene therapy for Canavan disease. 
  • Canavan disease is an ultra-rare inherited disorder that damages the ability of nerve cells (neurons) in the brain to send and receive messages.
  • Data from the first two participants show rapid and robust post-treatment decreases in N-acetylaspartate (NAA) in urine and, significantly, in cerebrospinal fluid (CSF) and brain tissue, to a degree not seen in available natural history data. 
  • Also Read: BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate.
  • Reduction in brain NAA is an early signal suggesting that BBP-812 administered IV has reached its target behind the blood-brain barrier and is expressing functional aspartoacylase enzyme. 
  • There is evidence in the scientific literature that lower NAA levels are associated with milder disease. 
  • BBP-812 has been well-tolerated, and no participants have experienced a treatment-related serious adverse event. 
  • The company said that while the data reported are still early and the final safety and efficacy profile of the investigational gene therapy remains to be fully established.
  • BridgeBio believes these data show the potential of BBP-812.
  • Price Action: BBIO shares are up 6.65% at $8.50 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.